Tumor mutational burden predicts neoantigen profiles and immunotherapy response in microsatellite stable tumors across different cancer types.

Front Immunol · 2025 · PMC12824007 · PMID 41583482

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with MSI-H tumors showed a trend toward better survival compared to those with MSS/TMB-L tumors in the TCGA-COADREAD dataset, but it was not significant.

also in 53,322 other papers

a clear trendno p-value reported

The MSS/TMB-H group did not show a clear trend in survival.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.